Takeda Yakuhin Kogyo KK

Latest Results (07.08.2024):

Revenue Growth

Takeda Yakuhin Kogyo KK reported a revenue of JPY 1,208.0 billion for the three-month period ended June 30, 2024, marking a 14.1% increase compared to the same period in the previous year. This growth was driven by favorable foreign exchange rates and strong performance in Plasma-Derived Therapies, Gastroenterology, Oncology, Rare Diseases, and Vaccines. However, this was partially offset by a decline in Neuroscience.

Operating Profit

For the three-month period ended June 30, 2024, Takeda Yakuhin Kogyo KK's operating profit was JPY 166.3 billion, a slight decrease of 1.3% compared to the same period in the previous year. This decline was influenced by increased costs in various operational areas, despite the overall revenue growth.

Net Profit

Takeda Yakuhin Kogyo KK achieved a net profit of JPY 95.2 billion for the three-month period ended June 30, 2024, representing a 6.5% increase from the same period in the previous year. This improvement in net profit was supported by the company's strong revenue performance and effective cost management strategies.

Dividends

Takeda Yakuhin Kogyo KK announced an annual dividend of JPY 196.00 per share for the fiscal year ending March 31, 2025, up from JPY 188.00 per share in the previous fiscal year. This increase reflects the company's commitment to returning value to its shareholders.

Financial Outlook

For the fiscal year ending March 31, 2025, Takeda Yakuhin Kogyo KK forecasts a revenue of JPY 4,350.0 billion, a 2.0% increase from the previous fiscal year. The company also projects a profit before income taxes of JPY 225.0 billion, a 5.1% increase, and a net profit attributable to owners of the company of JPY 58.0 billion, despite a significant decline in basic earnings per share.